MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Loss of membrane MHC class I protein expression in most of tumor cells in advanced melanomas predicts primary resistance to anti–CTLA-4, but not anti-PD1, treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another study, MHC I downregulation via transcriptional repression was associated with primary resistance to anti-CTLA-4 therapy but not to anti-PD-1 therapy, and the response to anti-PD-1 was more dependent on MHC II expression linked to an IFN-γ-regulated module of genes (97).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [97]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSalmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Cited by
Items 101–200 of 623
Epigenetic state determines the in vivo efficacy of STING agonist therapy
Falahat, R., Berglund, A., Perez-Villarroel, P., Putney, R. M., Hamaidi, I., Kim, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37217-1 · Cited by 94
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94
Dubrot, J., Lane-Reticker, S. K., Kessler, E. A., Ayer, A., Mishra, G., Wolfe, C. H., Zimmer, M. D., Du, P. P., Mahapatra, A., Ockerman, K. M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.001 · Cited by 91
CD28 co-stimulation: novel insights and applications in cancer immunotherapy
Lotze, M. T., Olejniczak, S. H., & Skokos, D. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01061-1 · Cited by 92
Ren, J., Li, N., Pei, S., Lian, Y., Li, L., Peng, Y., Liu, Q., Guo, J., Wang, X., Han, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153167 · Cited by 90
Bridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 89
Taniguchi, H., Chakraborty, S., Takahashi, N., Banerjee, A., Caeser, R., Zhan, Y. A., Tischfield, S. E., Chow, A. T., Nguyen, E. M., Quintanal-Villalonga, À., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado4618 · Cited by 89
Trefny, M. P., Kaiser, M., Stanczak, M. A., Herzig, P., Savic, S., Wiese, M. N., Lardinois, D., Laubli, H. P., Uhlenbrock, F., & Zippelius, A. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02558-z · Cited by 92
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
Giacomo, A. M. D., Covre, A., Finotello, F., Rieder, D., Danielli, R., Sigalotti, L., Giannarelli, D., Petitprez, F., Lacroix, L., Valente, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1335 · Cited by 90
Cheung, P. F., Yang, J., Fang, R., Borgers, A., Krengel, K., Stoffel, A., Althoff, K., Yip, C. W., Siu, E. H.-L., Ng, L. W. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27088-9 · Cited by 87
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Diab, A. K., Tykodi, S. S., Daniels, G. A., Maio, M., Curti, B. D., Lewis, K. D., Jang, S., Kalinka‐Warzocha, E., Puzanov, I. J., Spira, A. I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00675 · Cited by 86
Immune Therapy Resistance and Immune Escape of Tumors
Seliger, B., & Massa, C. (2021) · Cancers · doi:10.3390/cancers13030551 · Cited by 86
Brightman, S. E., Becker, A., Thota, R. R., Naradikian, M. S., Chihab, L. Y., Zavala, K. S., Premlal, A. L. R., Griswold, R. Q., Dolina, J. S., Cohen, E. E. W., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01543-9 · Cited by 85
mTOR and other effector kinase signals that impact T cell function and activity
Myers, D. R., Wheeler, B. D., & Roose, J. P. (2019) · Immunological Reviews · doi:10.1111/imr.12796 · Cited by 85
Janku, F., Han, S.-W., Doi, T., Amatu, A., Ajani, J. A., Kuboki, Y., Cortez, A., Cellitti, S. E., Mahling, P. C., Subramanian, K., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0722 · Cited by 84
Bretz, A. C., Parnitzke, U., Kronthaler, K., Dreker, T., Bartz, R., Hermann, F., Ammendola, A., Wulff, T., & Hamm, S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0745-3 · Cited by 83
Liu, X., Xu, J., Zhang, B., Liu, J., Liang, C., Meng, Q., Hua, J., Yu, X., & Shi, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1117-9 · Cited by 83
Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas
Wang, X., Waschke, B. C., Woolaver, R. A., Chen, Z., Zhang, G., Piscopio, A. D., Liu, X., & Wang, J. H. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0875 · Cited by 83
CD4 + T cell immunity against cutaneous melanoma encompasses multifaceted MHC II–dependent responses
Bawden, E., Wagner, T., Schröder, J., Effern, M., Hinze, D., Newland, L., Attrill, G. H., Lee, A. R., Engel, S., Freestone, D., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi9517 · Cited by 82
Cai, L., Michelakos, T. P., Deshpande, V., Arora, K. S., Yamada, T., Ting, D. T., Taylor, M. S., Castillo, C. F. F.-D., Warshaw, A. L., Lillemoe, K. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1401 · Cited by 82
Zebertavage, L., Alice, A. F., Crittenden, M. R., & Gough, M. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-64408-3 · Cited by 80
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy
Maggs, L., Sadagopan, A., Moghaddam, A. S., & Ferrone, S. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.07.006 · Cited by 80
Topchyan, P., Lin, S., & Cui, W. (2023) · Immune Network · doi:10.4110/in.2023.23.e41 · Cited by 82
Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
Ashrafizadeh, M., Zhang, W., Zou, R., Sethi, G., Klionsky, D. J., & Zhang, X. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106822 · Cited by 79
Balasubramanian, A., John, T., & Asselin-Labat, M.-L. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210961 · Cited by 79
Lei, P., Pereira, E. R., Andersson, P., Amoozgar, Z., van Wijnbergen, J. W., O’Melia, M. J., Zhou, H., Chatterjee, S., Ho, W. W., Posada, J. M., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221847 · Cited by 79
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 78
Landscape of tumoral ecosystem for enhanced anti-PD-1 immunotherapy by gut Akkermansia muciniphila
Zhu, Z., Huang, J., Zhang, Y., Hou, W., Chen, F., Mo, Y., & Zhang, Z. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114306 · Cited by 78
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma
Haymaker, C., Johnson, D. H., Murthy, R., Bentebibel, S.-E., Uemura, M. I., Hudgens, C. W., Safa, H., James, M. L., Andtbacka, R. H. I., Johnson, D. B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1546 · Cited by 76
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy
Shaver, K. A., Croom-Perez, T. J., & Copik, A. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679117 · Cited by 76
Paulson, K. G., Lahman, M. C., Chapuis, A. G., & Brownell, I. (2019) · International Immunology · doi:10.1093/intimm/dxz012 · Cited by 75
Pulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 75
Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
Mortezaee, K., & Majidpoor, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114824 · Cited by 72
Wawrzyniak, P., & Hartman, M. L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02294-x · Cited by 72
Immunotherapy-related biomarkers: Confirmations and uncertainties
Catalano, M., Iannone, L. F., Nesi, G., Nobili, S., Mini, E., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104135 · Cited by 71
Shaping the tumor immune microenvironment of SCLC: Mechanisms, and opportunities for immunotherapy
Chen, Y., Li, H., & Fan, Y. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102606 · Cited by 71
Such, L., Zhao, F., Liu, D. H., Thier, B., Le‐Trilling, V. T. K., Sucker, A., Coch, C., Pieper, N., Howe, S., Bhat, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131572 · Cited by 69
Kao, H., & Lou, P. (2019) · Head & Neck · doi:10.1002/hed.25930 · Cited by 70
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy
Khelil, M. B., Godet, Y., Abdeljaoued, S., Borg, C., Adotévi, O., & Loyon, R. (2022) · Cancers · doi:10.3390/cancers14010260 · Cited by 68
Weide, B., Eigentler, T., Catania, C., Ascierto, P. A., Cascinu, S., Becker, J. C., Hauschild, A., Romanini, A., Danielli, R., Dummer, R., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02383-z · Cited by 65
Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry
Martínez-Morilla, S., Villarroel‐Espíndola, F., Wong, P. F., Toki, M. I., Aung, T. N., Pelekanou, V., Bourke-Martin, B., Schalper, K. A., Kluger, H. M., & Rimm, D. L. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3340 · Cited by 65
The therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Grasso, C. S., Tsoi, J., Onyshchenko, M. I., Abril-Rodríguez, G., Ross‐Macdonald, P., Wind‐Rotolo, M., Champhekar, A. S., Medina, E., Torrejon, D. Y., Shin, D. S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.11.015 · Cited by 63
Self-citationPhosphoinositide 3-kinase signaling can modulate MHC class I and II expression
Chandrasekaran, S., Sasaki, M., Scharer, C. D., Kissick, H. T., Patterson, D. G., Magliocca, K. R., Seykora, J. T., Sapkota, B., Gutman, D. A., Cooper, L. A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0545 · Cited by 61
“To our knowledge these effects of PI3K signaling on MHCII induction in human cancer cells have not been previously reported despite the fact that tumor cell MHCII expression is being increasingly recognized for its relevance to anti-tumor immunity (57, 65, 66).”
BackgroundImmune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 61
Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy
Lagos, G., Izar, B., & Rizvi, N. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_289967 · Cited by 61
Cytotoxic CD4+ T cells in chronic viral infections and cancer
Malyshkina, A., Brüggemann, A., Paschen, A., & Dittmer, U. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1271236 · Cited by 62
Bai, X. L., Shoushtari, A. N., Warner, A. B., Si, L., Tang, B., Cui, C., Yang, X., Wei, X., Quach, H. T., Cann, C., et al. (2022) · British Journal of Dermatology · doi:10.1111/bjd.21241 · Cited by 61
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma
Wang, Y., Deng, J., Wang, L., Zhou, T., Yang, J., Tian, Z., Yang, J., Chen, H., Tang, X., Zhao, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000406 · Cited by 61
Effern, M., Glodde, N., Braun, M., Liebing, J., Boll, H. N., Yong, M. C. R., Bawden, E., Hinze, D., Konijnenberg, D., Daoud, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.007 · Cited by 58
Shoushtari, A. N., Chatila, W. K., Arora, A., Sánchez-Vega, F., Kantheti, H. S., Zamalloa, J. A. R., Krieger, P., Callahan, M. K., Warner, A. B., Postow, M. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4189 · Cited by 58
Self-citationThe immune-related role of beta-2-microglobulin in melanoma
Wang, C., Wang, Z., Yao, T., Zhou, J., & Wang, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.944722 · Cited by 58
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Veldman, J., Visser, L., van den Berg, A., & Diepstra, A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101931 · Cited by 56
Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma
Benboubker, V., Boivin, F., Dalle, S., & Caramel, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.873116 · Cited by 56
Resistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 55
Sadagopan, A., Michelakos, T. P., Boyiadzis, G., Ferrone, C. R., & Ferrone, S. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5970 · Cited by 55
The paradox of radiation and T cells in tumors
Gough, M. J., & Crittenden, M. R. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100808 · Cited by 55
Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
Petrova, V., Arkhypov, I., Weber, R., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072367 · Cited by 54
Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy
Lee, E. S., Shin, J. M., Son, S., Ko, H., Um, W., Song, S. H., Lee, J. A., & Park, J. H. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801320 · Cited by 54
Keenan, T. E., Guerriero, J. L., Barroso‐Sousa, R., Li, T., O’Meara, T. A., Giobbie‐Hurder, A., Tayob, N., Hu, J., Severgnini, M., Agudo, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25769-z · Cited by 54
Self-citationMullen, N. J., Shukla, S. K., Thakur, R. K., Kollala, S. S., Wang, D., Chaika, N. V., Santana, J. F., Miklavcic, W. R., LaBreck, D. A., Mallareddy, J. R., et al. (2024) · eLife · doi:10.7554/elife.87292 · Cited by 54
Zheng, N., Wang, T., Luo, Q., Liu, Y., Yang, J., Zhou, Y., Xie, G., Ma, Y., Yuan, X., & Shen, L. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2210959 · Cited by 54
Lester, D. K., Burton, C., Gardner, A., Innamarato, P., Kodumudi, K. N., Liu, Q., Adhikari, E., Ming, Q., Williamson, D. B., Frederick, D. T., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00506-7 · Cited by 54
Li, X., Wang, Y., Li, X., Feng, G., Hu, S., & Bai, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638763 · Cited by 53
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 52
Du, K., Wei, S., Wei, Z., Frederick, D. T., Miao, B., Moll, T. O. C., Tian, T., Sugarman, E. T., Gabrilovich, D. I., Sullivan, R. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26299-4 · Cited by 52
Charrier, M., Mezquita, L., Lueza, B., Dupraz, L., Planchard, D., Remón, J., Caramella, C., Cassard, L., Boselli, L., Reiners, K. S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.017 · Cited by 52
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Fountzilas, E., Kurzrock, R., Vo, H. H., & Tsimberidou, A. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab067 · Cited by 50
Yin, X., Song, X., Deng, W., BLAKE, N. W., Luo, X., & Meng, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1483454 · Cited by 50
Waks, A. G., Keenan, T. E., Li, T., Tayob, N., Wulf, G. M., Richardson, E. T., Attaya, V., Anderson, L., Mittendorf, E. A., Overmoyer, B. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005119 · Cited by 50
Chen, Y., Wang, X., Deng, X., Zhang, Y., Liao, R., Li, Y., Yang, H., & Chen, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.676922 · Cited by 50
Yao, H., Huang, C., Zou, J., Liang, W., Zhao, Y., Yang, K., Zhong, Z., Zhou, S., Li, J., Li, Y., et al. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12484 · Cited by 50
Noviello, T., Giacomo, A. M. D., Caruso, F. P., Covre, A., Mortarini, R., Scala, G., Costa, M. C., Coral, S., Fridman, W. H., Sautès‐Fridman, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40994-4 · Cited by 50
Silva, P. D., Aiello, M. M., Gu‐Trantien, C., Migliori, E., Willard-Gallo, K. E., & Solinas, C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33415 · Cited by 50
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
Shklovskaya, E., Lee, J., Lim, S. Y., Stewart, A., Pedersen, B., Ferguson, P. M., Saw, R. P. M., Thompson, J. F., Shivalingam, B., Carlino, M. S., et al. (2020) · Cancers · doi:10.3390/cancers12113374 · Cited by 49
Friedman, C. F., Spencer, C. N., Cabanski, C. R., Panageas, K. S., Wells, D. K., Ribas, A., Tawbi, H. A., Tsai, K. K., Postow, M. A., Shoushtari, A. N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003853 · Cited by 49
Self-citationMetal complex-based liposomes: Applications and prospects in cancer diagnostics and therapeutics
Wang, Z., Li, J., Lin, G., He, Z., & Wang, Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.012 · Cited by 49
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
Olbryt, M., Rajczykowski, M., & Widłak, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114071 · Cited by 48
Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma
Lee, P. C., Klaeger, S., Le, P. M., Korthauer, K. D., Cheng, J., Ananthapadmanabhan, V., Frost, T. C., Stevens, J. D., Wong, A. Y. L., Iorgulescu, J. B., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci151666 · Cited by 47
Self-citationExploration of the immune cell infiltration-related gene signature in the prognosis of melanoma
Zeng, Y., Zeng, Y., Yin, H., Chen, F., Wang, Q., Yu, X., & Zhou, Y. (2021) · Aging · doi:10.18632/aging.202279 · Cited by 47
Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S. E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4380 · Cited by 46
Self-citationMHC heterogeneity and response of metastases to immunotherapy
Algarra, I., Garrido, F., & Garcia-Lora, A. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09964-4 · Cited by 46
Extracellular vesicles in pancreatic cancer immune escape: Emerging roles and mechanisms
Liu, C., He, D., Li, L., Zhang, S., Wang, L., Fan, Z., & Wang, Y. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106364 · Cited by 46
Lin, A., Qiu, Z., Zhang, J., & Luo, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.630773 · Cited by 45
Lymphatic system regulation of anti-cancer immunity and metastasis
Lei, P., Fraser, C. S., Jones, D., Ubellacker, J. M., & Padera, T. P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1449291 · Cited by 45
Current Understanding of Microbiomes in Cancer Metastasis
Liu, J., Luo, F., Wen, L., Zhao, Z., & Sun, H. (2023) · Cancers · doi:10.3390/cancers15061893 · Cited by 45
Integrated molecular drivers coordinate biological and clinical states in melanoma
Conway, J. R., Dietlein, F., Taylor-Weiner, A. N., AlDubayan, S. H., Vokes, N. I., Keenan, T. E., Reardon, B. M., He, M. X., Margolis, C. A., Weirather, J. L., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00739-1 · Cited by 45
Self-citationBiomarkers for predicting the efficacy of immune checkpoint inhibitors
Wang, C., Wang, H.-N., & Wang, L. (2022) · Journal of Cancer · doi:10.7150/jca.65012 · Cited by 44
The dichotomous role of immunoproteasome in cancer: Friend or foe?
Chen, B., Zhu, H., Yang, B. Y., & Cao, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.005 · Cited by 44
Gately, S. T. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_10 · Cited by 43
Emerging Biomaterials Imaging Antitumor Immune Response
Ma, X., Zhang, M., Wang, J., Zhang, T., Xue, P., Kang, Y., Sun, Z., & Xu, Z. (2022) · Advanced Materials · doi:10.1002/adma.202204034 · Cited by 43
Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development
Grzywa, T. M., Justyniarska, M., Nowis, D., & Gołąb, J. (2021) · Cancers · doi:10.3390/cancers13040870 · Cited by 43
Zhang, P., Du, Y., Bai, H., Wang, Z., Duan, J., Wang, X., Zhong, J. Y., Wan, R., Xu, J., He, X., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02598-5 · Cited by 43
Role of Surgery for Metastatic Melanoma
Enomoto, L. M., Levine, E. A., Shen, P., & Votanopoulos, K. I. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.011 · Cited by 43
Leveraging microenvironmental synthetic lethalities to treat cancer
Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143765 · Cited by 42
Tissue Multiplex Analyte Detection in Anatomic Pathology – Pathways to Clinical Implementation
Wharton, K. A., Wood, D., Manesse, M., Maclean, K. H., Leiß, F., & Żuraw, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.672531 · Cited by 42
Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers
Acebes-Fernández, V., Landeira‐Viñuela, A., Juanes‐Velasco, P., Hernández, Á., Otazo‐Pérez, A., Manzano-Román, R., Góngora, R., & Fuentes, M. (2020) · Nanomaterials · doi:10.3390/nano10071274 · Cited by 42
Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
Garces, A. I., Au, L., Mason, R., Thomas, J. M., & Larkin, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1649657 · Cited by 42
Metadata
- Authors
- Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., Weirather, J. L., Wolchok, J. D., Postow, M. A., Pavlick, A. C., Chesney, J., & Hodi, F. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Bristol-Myers Squibb (United States) (US)
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- NYU Langone Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Louisville (US)
- Corresponding author
- Rodig, Scott J.
- Hodi, F. Stephen
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-07-18
- Volume
- 10
- Issue
- 450
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2883970691
- Cited by
- 579
- References
- 59
- Citations by year
- 2026: 38 · 2025: 48 · 2024: 75 · 2023: 101 · 2022: 94 · 2021: 79 · 2020: 76 · 2019: 55 · 2018: 12
- FWCI
- 20.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Funded by Bristol-Myers Squibb (N/A)
- NIH/NCI Cancer Center (P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- metastatic melanoma, MHC class I expression, MHC class II expression, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint inhibitors, interferon-gamma, innate immunity, tumor antigen presentation, antitumor immunity, predictive biomarkers
- MeSH terms
- HLA Antigens, Humans, Immunity, Innate, Immunotherapy, Melanoma, Transcription, Genetic, Gene Expression Regulation, Neoplastic, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.